Coronvirus tally: FDA pulls Glaxo COVID treatment ahead of panel meeting on next steps for 2022
GlaxoSmithKline's IV drug for COVID-19 should no longer be used because it is likely ineffective against the omicron subvariant that now accounts for most U.S....